Last updated: September 8, 2026
Sulfamethoxazole-trimethoprim, also called trimethoprim-sulfamethoxazole or TMP-SMX, is a mature generic antibacterial combination with broad clinical use and limited patent protection. Its financial profile is driven by prescription volume, low unit prices, hospital and retail procurement, shortage risk, and the number of competing manufacturers rather than branded pricing power. The combination has no meaningful remaining originator exclusivity in the United States, and generic entry risk is high.
What is the current market position of sulfamethoxazole-trimethoprim?
Sulfamethoxazole-trimethoprim is a low-cost, multisource antibiotic marketed primarily as a generic. It is available in tablets, double-strength tablets, oral suspension, and injectable formulations. The most commercially important strengths are:
| Product form |
Common strength |
Principal use |
| Tablet |
80 mg/400 mg |
Standard adult dosing |
| Double-strength tablet |
160 mg/800 mg |
Most common adult prescription |
| Oral suspension |
200 mg/40 mg per 5 mL |
Pediatric and swallowing-limited patients |
| Injection |
80 mg/16 mg per mL |
Hospital use |
The drug is used for urinary tract infections, skin and soft-tissue infections, selected respiratory infections, shigellosis, and Pneumocystis jirovecii pneumonia. Resistance trends and adverse-event concerns limit use in some indications, but the combination remains clinically important because it is inexpensive, orally available, and included in several treatment guidelines.
The commercial market is fragmented. Multiple generic manufacturers compete for retail, hospital, government, and group-purchasing-organization contracts. Product-level revenue is generally not disclosed by manufacturers because sulfamethoxazole-trimethoprim is included within broader generic portfolios.
When does sulfamethoxazole-trimethoprim lose exclusivity?
Sulfamethoxazole-trimethoprim lost meaningful U.S. market exclusivity decades ago. The original combination products were approved in the 1960s, and the core composition and use patents have expired. The product is therefore subject to ordinary generic competition rather than an active branded-exclusivity period.
The FDA’s Orange Book framework lists approved products and any relevant patent or exclusivity information submitted for listed drugs. For a mature combination such as TMP-SMX, the commercial question is not the duration of remaining exclusivity but the number of active generic suppliers and the availability of manufacturing capacity (FDA, n.d.-a).
What is the patent expiration date for Bactrim and generic TMP-SMX?
The original Bactrim-related patent estate is expired. No core patent should prevent a qualified manufacturer from marketing standard sulfamethoxazole-trimethoprim tablets or suspension in the United States.
Product-specific patents may historically have covered particular formulations, dosage forms, or manufacturing processes. Those rights do not create a current market barrier for conventional generic tablets and suspensions. Any patent analysis for a specific supplier must distinguish:
- Expired compound or combination patents.
- Expired formulation patents.
- Process patents that may not block sale of the finished product.
- Patents listed for a specific NDA or ANDA.
- Regulatory exclusivity, which is separate from patent protection.
The key commercial conclusion is that standard TMP-SMX is an off-patent product with high generic substitutability.
What is the FDA regulatory status of sulfamethoxazole-trimethoprim?
Sulfamethoxazole-trimethoprim is FDA-approved in several dosage forms and is available through abbreviated new drug applications. Generic manufacturers must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. The product is not a biologic and does not face the biosimilar pathway.
The FDA label includes warnings involving severe skin reactions, hypersensitivity, hematologic toxicity, hyperkalemia, renal impairment, and interactions with drugs such as warfarin. These risks can affect prescribing and monitoring but do not create regulatory exclusivity (FDA, n.d.-b).
The drug is a prescription antibacterial. It does not have a current new-drug exclusivity period comparable to recently approved antibiotics. Regulatory value is based on manufacturing approval, supply reliability, and compliance history.
What patents protect sulfamethoxazole-trimethoprim?
No active foundational patent is expected to protect the sulfamethoxazole-trimethoprim combination in its conventional dosage forms. The relevant IP categories are:
| IP category |
Commercial status |
| Combination composition |
Expired |
| Conventional tablet formulation |
Expired or commercially unrestrictive |
| Oral suspension |
Mature generic technology |
| Injectable formulation |
Mature generic technology, with manufacturing complexity |
| Treatment methods |
Historic and generally expired |
| Manufacturing processes |
Potentially supplier-specific, but not usually a market-wide barrier |
| Packaging and device technology |
Limited relevance for standard products |
Method-of-use patents are unlikely to materially restrict the main indications. Clinical use is established, generic substitution is routine, and the product is used across several therapeutic categories.
How strong is the patent estate for TMP-SMX?
The patent estate is weak from a branded-product perspective and has little ability to support premium pricing. Its strategic value is close to zero for lifecycle management based solely on conventional tablets or suspension.
Manufacturing know-how can still matter. Control of impurity profiles, stability, particle characteristics, dissolution, and injectable formulation processes can create operational advantages. These advantages are trade-secret or process-quality advantages rather than durable exclusion rights.
Are there Paragraph IV challenges for sulfamethoxazole-trimethoprim?
Paragraph IV litigation is not a major current market issue for standard sulfamethoxazole-trimethoprim products because the principal patents associated with the original products have expired. Paragraph IV certifications are most relevant when an ANDA applicant challenges an unexpired patent listed in the Orange Book. A mature, multisource product generally has little incentive for large-scale patent litigation unless a supplier introduces a protected reformulation or a new dosage form.
The more relevant competitive events are:
- ANDA approvals.
- Manufacturer withdrawals.
- FDA warning letters or manufacturing remediation.
- Drug-shortage listings.
- Contract changes with wholesalers and hospitals.
- Changes in reimbursement and pharmacy purchasing.
What formulations are protected by sulfamethoxazole-trimethoprim patents?
Conventional TMP-SMX tablets and oral suspension are not protected by a commercially meaningful active formulation estate. The injectable form can require more specialized manufacturing and quality controls, but technical complexity does not equal patent exclusivity.
Formulation-specific commercial differentiation may involve:
- Improved suspension stability.
- Taste masking.
- Unit-dose packaging.
- Pediatric dosing devices.
- Preservative systems.
- Ready-to-use injectable presentations.
- Reduced waste in hospital settings.
These features can support procurement preferences or modest product differentiation. They are unlikely to create sustained pricing power without regulatory exclusivity or a defensible patent.
What is the Orange Book status of sulfamethoxazole-trimethoprim?
The Orange Book is relevant for confirming reference-listed drugs, patents, and exclusivity. For ordinary TMP-SMX tablets and suspension, the expected status is mature generic availability with no remaining core exclusivity blocking ANDA competition.
The Orange Book does not measure market share, supply reliability, product quality, or the number of commercially active suppliers. A product may have several approved ANDAs while only a smaller number of manufacturers actively sell it. This distinction matters because nominal approval count can overstate effective competition.
What is the financial trajectory for sulfamethoxazole-trimethoprim?
The financial trajectory is best characterized as stable-to-declining nominal pricing with recurring demand and limited revenue expansion. The drug is unlikely to generate substantial growth through price increases. Revenue depends on volume, product mix, customer retention, and supply continuity.
Revenue drivers
- Prescription volume remains supported by low acquisition cost and broad clinical familiarity.
- Double-strength tablets account for a significant share of adult demand.
- Hospital demand supports injectable sales but is more sensitive to supply interruptions and contract awards.
- Pediatric suspension demand is smaller but can carry better unit economics than standard tablets.
- Shortages can temporarily improve realized pricing for suppliers with available inventory.
Revenue constraints
- Multiple generic competitors limit pricing power.
- Pharmacy benefit managers and wholesalers exert purchasing pressure.
- State Medicaid and government programs favor low-cost suppliers.
- Antibiotic stewardship reduces unnecessary utilization.
- Resistance can shift prescribing toward alternative antibiotics.
- Raw-material and manufacturing concentration can compress margins or disrupt supply.
Public companies generally report TMP-SMX within broad generic or hospital-product segments. They do not typically disclose revenue, gross margin, or market share for the molecule alone. A standalone market-size figure therefore has limited reliability unless tied to a defined geography, channel, dosage form, and measurement source.
How do generic manufacturers compete in the TMP-SMX market?
Competition is based on cost, supply reliability, FDA compliance, and channel access. Brand recognition has limited value because pharmacists and health systems routinely substitute approved generics.
| Competitive factor |
Effect on market position |
| Lowest approved cost |
Important in retail and government channels |
| Consistent supply |
Critical during shortages |
| Broad dosage-form portfolio |
Improves hospital and wholesaler access |
| FDA inspection history |
Can determine procurement eligibility |
| Packaging flexibility |
Helps institutional and retail customers |
| Distributor relationships |
Supports inventory placement |
| Manufacturing redundancy |
Reduces interruption risk |
Potential suppliers include large generic companies, specialty generic manufacturers, and contract manufacturers. The relevant competitive set changes by dosage form and country. A tablet supplier may not compete effectively in injectable products, and a manufacturer with approved products may have no current commercial sales.
What patent litigation affects sulfamethoxazole-trimethoprim?
Patent litigation is not the principal risk for conventional TMP-SMX. The product’s age and broad generic availability reduce the expected value of patent disputes. Current commercial disputes are more likely to involve:
- Supply agreements.
- Product-quality claims.
- Antitrust or contracting issues.
- Drug-shortage allocation.
- Regulatory enforcement.
- Hospital procurement contracts.
- Product liability associated with adverse reactions.
No settlement agreement is likely to have material relevance to the mature core product absent a newly developed formulation or a jurisdiction-specific patent dispute.
What generic entry risks exist?
Generic entry risk is structurally high because the product is off patent, clinically established, and technically familiar. A new entrant could capture share through lower pricing, reliable supply, or a differentiated dosage form.
The main risk to incumbent suppliers is not a single generic launch. It is cumulative price erosion from multiple suppliers. Market share can also move quickly after a manufacturing disruption because wholesalers and hospital buyers reallocate purchases to available sources.
For investors and licensors, the central diligence questions are:
- Is the supplier actively marketing the product?
- Does it have more than one manufacturing site?
- Is the active pharmaceutical ingredient sourced from multiple qualified vendors?
- Has the product appeared on FDA shortage or discontinuation lists?
- Is the supplier exposed to warning letters or remediation?
- Does the product have meaningful institutional contracts?
- Is injectable capacity available?
How does sulfamethoxazole-trimethoprim compare with competing antibiotics?
TMP-SMX competes with nitrofurantoin, fosfomycin, fluoroquinolones, beta-lactams, doxycycline, and other agents. Its competitive position varies by infection and resistance pattern.
| Drug class |
TMP-SMX competitive position |
| Nitrofurantoin |
Strong competitor for uncomplicated urinary tract infection |
| Fosfomycin |
Alternative for selected urinary infections |
| Fluoroquinolones |
Broader use in some settings but greater safety restrictions |
| Beta-lactams |
Alternative when sulfonamides are unsuitable |
| Doxycycline |
Competes in some skin and respiratory indications |
| Intravenous antibiotics |
TMP-SMX retains a role in selected severe or opportunistic infections |
TMP-SMX’s advantages are low cost, oral availability, and established clinical use. Its disadvantages include allergy risk, drug interactions, renal dosing concerns, and local resistance variability.
What is the geographic coverage of TMP-SMX?
Sulfamethoxazole-trimethoprim is sold globally under different names, including co-trimoxazole. It is included in international essential-medicines frameworks and is widely used in lower-cost healthcare systems. Market economics differ substantially by region.
The United States has a highly competitive generic market with strong payer and wholesaler pressure. European markets often use centralized procurement and national reimbursement controls. Emerging markets may have greater use of branded generics, but regulatory oversight and quality consistency vary by country.
The combination’s international reach supports recurring volume but does not necessarily translate into high supplier profitability. Many markets treat it as a low-cost essential medicine.
What manufacturing and IP barriers affect the market?
Manufacturing barriers are more important than intellectual-property barriers. The principal operational risks are:
- API supply concentration.
- Impurity control.
- Batch failure.
- Dissolution and content-uniformity problems.
- Suspension stability.
- Sterility requirements for injection.
- Packaging and serialization compliance.
- FDA or other regulator inspection findings.
For tablets, entry barriers are relatively low for established generic manufacturers. Injectable products have higher technical and compliance barriers. The strongest market positions are likely to belong to suppliers with reliable API procurement, redundant production, and established distribution rather than to companies holding exclusive patents.
Key Takeaways
- Sulfamethoxazole-trimethoprim is a mature, off-patent generic antibiotic.
- Core Bactrim and TMP-SMX exclusivity expired decades ago.
- No meaningful active patent estate is expected to block conventional generic tablets or suspension.
- Paragraph IV litigation and patent settlements are not central market drivers.
- Revenue is recurring but low-margin, with limited product-level disclosure.
- Market share depends on price, supply reliability, FDA compliance, and distribution.
- Injectable products have greater manufacturing complexity than tablets.
- Generic price erosion is persistent, while shortages can create temporary pricing opportunities.
- The principal investment risks are supply disruption, API concentration, regulatory enforcement, and resistance-driven volume decline.
- Biosimilar risk is irrelevant because TMP-SMX is a small-molecule drug, not a biologic.
FAQs
Is sulfamethoxazole-trimethoprim still profitable for generic manufacturers?
It can be profitable at scale, but margins are generally constrained by multisource competition. Profitability is strongest for suppliers with low manufacturing costs, reliable supply, and access to institutional or high-volume contracts.
Is Bactrim still protected by patents?
The original Bactrim-related exclusivity has expired. Any remaining patents associated with a specific product or formulation would need to be reviewed in the applicable Orange Book and jurisdictional records, but they are not expected to block standard generic TMP-SMX products.
Can a new company enter the sulfamethoxazole-trimethoprim market?
Yes. A qualified manufacturer can pursue an ANDA or other applicable regulatory pathway for an approved dosage form. Commercial success would depend more on cost and supply execution than on patent strategy.
Does antibiotic resistance threaten TMP-SMX revenue?
Yes. Resistance can reduce use in indications where susceptibility is declining. The effect is regional and indication-specific because prescribing decisions depend on local antibiograms and treatment guidelines.
Are sulfamethoxazole-trimethoprim shortages a patent problem?
No. Shortages are more likely to reflect manufacturing capacity, API availability, quality remediation, procurement economics, or supplier exits than patent restrictions.
References
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-b). Bactrim and Bactrim DS prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
World Health Organization. (2023). WHO model list of essential medicines, 23rd list. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
